Rheumatology and Therapy, 2023 Introduction This post hoc analysis of the phase 3 rheumatoid arthritis (RA) filgotinib clinical trial program assessed the effect of filgotinib on body mass index (BMI) in patients with RA and the impact of BMI on the efficacy and safety of filgotinib ...
Hans-Dieter Orzechowski +2 more
exaly +7 more sources
Comparison of the Efficacy of Different Doses of Filgotinib in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis Based on the RCTs [PDF]
Dose-ResponseObjective This study compared the efficacy of different doses of filgotinib (100 mg vs 200 mg) in the treatment of rheumatoid arthritis (RA). Methods We conducted a systematic review of 4 electronic databases up to January 2025.
Xia Ye +7 more
doaj +2 more sources
Filgotinib for the treatment of rheumatoid arthritis [PDF]
Expert Opinion on Investigational Drugs, 2017 Biologics were the first targeted therapies for rheumatoid arthritis (RA), having in common high clinical efficacy. Being proteins, they are administered parenterally. The first oral targeted small molecules approved for RA are competitive inhibitors of the Janus kinase (JAK) enzyme family which mediate signalling for a cytokine subset important in RA ...
Peter C. Taylor, Serafim Kiriakidis
exaly +3 more sources
Rheumatology and Therapy, 2020 Introduction The Janus kinase (JAK) inhibitor therapeutic class has shown significant clinical benefit in the treatment of rheumatoid arthritis (RA).
Peter C. Taylor +2 more
exaly +2 more sources
Geographic Analysis of the Safety and Efficacy of Filgotinib in Rheumatoid Arthritis
Rheumatology and Therapy, 2022 Plain Language Summary Clinical trials in rheumatoid arthritis recruit too few patients from diverse ethnic backgrounds to be able to identify differences in treatment outcomes.
Bernard Combe +6 more
doaj +4 more sources
Filgotinib inhibits METTL3-mediated m6A of EIF3A by targeting ERG-TBP to suppress PDAC progression JAK-STAT3-independently [PDF]
npj Precision OncologyPancreatic ductal adenocarcinoma (PDAC) is a highly aggressive tumor. EIF3A has been identified as a reader of N6-methyladenosine (m6A) modification, influencing the translation levels of various molecules and functioning as an oncogene.
Chaolei Zhang +8 more
doaj +2 more sources
A disproportionality analysis of FDA adverse event reporting system (FAERS) events for filgotinib. [PDF]
PLoS ONEBackgroundAlthough filgotinib, a selective Janus kinase 1 inhibitor, has been increasingly applied in the treatment of inflammatory diseases, its comprehensive safety profile remains insufficiently characterized.
Yinli Shi +7 more
doaj +2 more sources
Optimal use and cycling strategies of Janus kinase inhibitors in ulcerative colitis: current evidence and clinical implications from the KASID Guidelines Task Force Team [PDF]
Intestinal ResearchJanus kinase (JAK) inhibitors are an important treatment option for ulcerative colitis, providing rapid onset of action, oral administration, and efficacy even after biologic failure. The 3 approved agents—tofacitinib, filgotinib, and upadacitinib—differ
Seung Min Hong +20 more
doaj +2 more sources
Clinical and Experimental Gastroenterology, 2022 Arianna Dal Buono,1 Roberto Gabbiadini,1 Virginia Solitano,1,2 Edoardo Vespa,1,2 Tommaso Lorenzo Parigi,1,2 Alessandro Repici,2,3 Antonino Spinelli,1,2,4 Alessandro Armuzzi1,2 1IBD Center, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy ...
Antonino Spinelli +2 more
exaly +2 more sources
JAK inhibitors and adverse cardiovascular events: Class effect or molecule-specific risk? [PDF]
Frontiers in PharmacologyJanus kinase inhibitors (JAKis) have established themselves as a valuable treatment option in treating rheumatoid arthritis and other immune-mediated inflammatory diseases, providing rapid and effective disease control across multiple refractory ...
Mislav Radić +10 more
doaj +2 more sources